Suchen
Biogen Inc
BIIBZur Watchlist hinzufügen
199.590USD
+2.400+1.22%
Handelsschluss 06/24, 16:00（ET）Kurse um 15 Minuten verzögert
29.47BMarktkapitalisierung
21.35KGV TTM
mehr Informationen über Biogen Inc Unternehmen
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Biogen Inc Informationen
BörsenkürzelBIIB
Name des UnternehmensBiogen Inc
IPO-datumSep 17, 1991
CEOViehbacher (Christopher A)
Anzahl der mitarbeiter7605
WertpapierartOrdinary Share
GeschäftsjahresendeSep 17
Addresse225 Binney Street
StadtCAMBRIDGE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02142
Telefon17814642000
Websitehttps://www.biogen.com/
BörsenkürzelBIIB
IPO-datumSep 17, 1991
CEOViehbacher (Christopher A)
Führungskräfte von Biogen Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
61.89K
--
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
27.84K
-4.94%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
22.10K
+20.79%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
19.75K
+0.69%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
16.08K
+30.17%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.82K
+11.74%
Mr. Jesus B. Mantas
Mr. Jesus B. Mantas
Independent Director
Independent Director
8.89K
+16.92%
Ms. Priya Singhal, M.D.
Ms. Priya Singhal, M.D.
Executive Vice President, Head of Development
Executive Vice President, Head of Development
8.04K
-0.01%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
6.45K
+31.09%
Dr. Adam James Keeney, Ph.D.
Dr. Adam James Keeney, Ph.D.
Executive Vice President, Head of Corporate Development
Executive Vice President, Head of Corporate Development
6.37K
+7.60%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
61.89K
--
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
27.84K
-4.94%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
22.10K
+20.79%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
19.75K
+0.69%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
16.08K
+30.17%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.82K
+11.74%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Biogen Inc?
Die fünf größten Anteilseigner von Biogen Inc sind: Ms. Susan H. Alexander, Esq., J.D.
Wie viele Institutionen halten Anteile an Biogen Inc (BIIB)?
Mit Stand vom 2026Q1 halten 2085 Institutionen Anteile an Biogen Inc, mit einem Gesamtmarktwert von etwa 144.76M, was 98.05% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -3983853.00 gestiegen.
Was ist die größte Einnahmequelle von Biogen Inc?
Am 2026Q1 erzielte das Geschäft mit Spinal Muscular Atrophy-SPINRAZA für Biogen Inc den höchsten Umsatz in Höhe von 2.15B, was 21.78% des Gesamtumsatzes entspricht.
